People with atypical hemolytic uremic syndrome (aHUS) who’ve had a kidney transplant can safely switch from Soliris (eculizumab) to Ultomiris (ravulizumab-cwvz) without risking a recurrence of the disease. That’s according to a real-world study that also found that blood and kidney-related disease markers remained stable after the switch, and…
People with atypical hemolytic uremic syndrome (aHUS) who stop taking Soliris (eculizumab) have a 16.5% higher risk of having a relapse, while those who continue treatment have a 76% lower relapse risk, a meta-analysis of published studies suggests. The differences, however, were only seen in case-control studies, not…
Adults with atypical hemolytic uremic syndrome (aHUS) in the U.K. who didn’t receive treatment with Soliris (eculizumab) had a 43% chance of developing end-stage kidney disease within five years, according to a study that found this severe form of kidney damage was less likely in children within the…
Soliris (eculizumab) helped ease disease symptoms for a woman with multiple myeloma who developed atypical hemolytic uremic syndrome (aHUS) as a complication of a viral infection caused by H1N1 influenza — also known as influenza A, or swine flu. “The prompt recognition and initiation of anti-complement therapy played…
Most people with atypical hemolytic uremic syndrome (aHUS) who are stable on Soliris (eculizumab) can stop treatment after at least six months without having a relapse, provided that they’re carefully monitored, a recent study reported. Scientists expect that this could prevent treatment-related complications and burden for patients, while…
Atypical hemolytic uremic syndrome (aHUS) can occur as a rare complication of surgery involving the urinary tract, according to a report from Italy detailing the case of a woman in her 40s who developed the condition after undergoing a procedure to remove kidney stones. The patient, who had a…
A 38-year-old woman who developed pregnancy-associated atypical hemolytic uremic syndrome (P-aHUS) after giving birth via cesarean section successfully recovered following treatment with Soliris (eculizumab), a case report from China shows. Genetic testing revealed the presence of a mutation in the CFH gene, which likely contributed to her condition.
Short-term use of Soliris (eculizumab) in India — where the drug was approved just this year for treating two rare diseases — was effective for five children with atypical hemolytic uremic syndrome (aHUS), according to a new report. While the antibody therapy has been approved as an aHUS…
Adults with atypical hemolytic uremic syndrome (aHUS) who start Soliris (eculizumab) within seven days after their symptoms start see the best outcomes, a small real-world study in Western China suggests. The patients showed significantly improved blood and kidney function, and a reduced need for dialysis, while most given…
Atypical hemolytic uremic syndrome (aHUS) can occur concurrently with disseminated intravascular coagulation (DIC), a blood disorder marked by similar symptoms, but that has different underlying causes. The case of a boy with both aHUS and DIC was highlighted in the paper, “A Case Report of Atypical…
Get regular updates to your inbox.